BioNxt Solutions Announces Option Grants

Rhea-AI Summary

BioNxt Solutions (CSE:BNXT, OTCQB:BNXTF, FSE:4XT) granted an aggregate of 750,000 stock options to insiders, consultants and an employee, exercisable at $0.33 per share for three years, and a further 2,650,000 options to insiders and a consultant at the same price for five years. All options vested immediately.

According to BioNxt Solutions, the grants were made under its stock option plan, last approved by shareholders on November 7, 2025, and the options and underlying shares are subject to a four‑month hold period under Canadian Securities Exchange policies.

Positive

• 3,400,000 stock options granted at $0.33 under approved plan
• Option plan last approved by shareholders on November 7, 2025

Negative

• Immediate vesting of 3,400,000 options at $0.33 exercise price
• Options and underlying shares subject to four‑month hold period

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / July 31, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has granted an aggregate of 750,000 stock options ("Options") pursuant to the Company's stock option plan (the "Option Plan") to certain insiders, consultants and an employee of the Company, each Option entitling the holder thereof to acquire one common share of the Company (a "Common Share") at an exercise price of $0.33 for a period of three years. All such Options vested immediately.

Additionally, the Company granted an aggregate of 2,650,000 Options pursuant to the Option Plan to certain insiders and a consultants of the Company, each Option entitling the holder thereof to acquire one Common Share of the Company at an exercise price of $0.33 for a period of five years. All such Options vested immediately.

The Option Plan was last approved by the shareholders of the Company on November 7, 2025.

The Options and any underlying common shares in the capital of the Company will be subject to a four month hold period pursuant to the policies of the Canadian Securities Exchange.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects.

With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Email: investor.relations@bionxt.com

Wolfgang Probst
Co-Founder, CFO & Director
Phone: +49 151 25284192

Hugh Rogers
Co-Founder, CEO & Director
Phone: +1 604-250-6162

Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

What stock options did BioNxt Solutions (OTCQB:BNXTF) grant on July 31, 2026?

BioNxt Solutions granted an aggregate of 3,400,000 stock options at an exercise price of $0.33 per share. According to BioNxt Solutions, 750,000 options have a three‑year term and 2,650,000 options have a five‑year term, with all options vesting immediately.

Who received the new BioNxt Solutions (BNXTF) stock option grants and on what terms?

The options were granted to certain insiders, consultants and an employee of BioNxt Solutions. According to BioNxt Solutions, each option allows the holder to acquire one common share at $0.33, with either a three‑year or five‑year term, and all options vested immediately.

What is the exercise price and duration of the new BioNxt Solutions (BNXTF) options?

All newly granted BioNxt Solutions options carry a $0.33 exercise price per common share. According to BioNxt Solutions, 750,000 options are exercisable for three years and 2,650,000 options are exercisable for five years from the grant date, with immediate vesting.

Are the July 31, 2026 BioNxt Solutions (BNXTF) option grants subject to a hold period?

Yes, the options and any underlying common shares are subject to a four‑month hold period. According to BioNxt Solutions, this restriction is imposed under the policies of the Canadian Securities Exchange and applies to all the newly granted options and resulting shares.

When was the BioNxt Solutions (BNXTF) stock option plan last approved by shareholders?

BioNxt Solutions’ stock option plan was last approved by shareholders on November 7, 2025. According to BioNxt Solutions, the July 31, 2026 grants of 3,400,000 options were made pursuant to this shareholder‑approved option plan under Canadian Securities Exchange policies.

How many BioNxt Solutions (BNXTF) options granted on July 31, 2026, vested immediately?

All 3,400,000 options granted on July 31, 2026 vested immediately. According to BioNxt Solutions, both the 750,000 three‑year options and the 2,650,000 five‑year options became fully vested on grant, while remaining subject to a four‑month hold period on any underlying shares.